| ￥3500 | |
| Z05547-100 | |
|
|
|
|
|
|
|
|
|
| Species | Human | ||||
| Protein Construction |
|
||||
| Purity | > 90% as determined by Bis-Tris PAGE | ||||
| Endotoxin Level | Less than 1EU per μg by the LAL method. | ||||
| Biological Activity | Measured by its binding ability in a functional ELISA. Test result was comparable to standard batch. | ||||
| Expression System | HEK293 | ||||
| Theoretical Molecular Weight | 50.24 kDa | ||||
| Apparent Molecular Weight | Due to glycosylation, the protein migrates to 55-70 kDa based on Bis-Tris PAGE result. | ||||
| Formulation | Supplied as 0.22 μm filtered solution in 20mM PB, 500mM NaCl, 200mM L-Arginine (pH 7.4). | ||||
| Concentration | Verified by one or more methods from 0.64mg/ml A280/Bioactivity/BCA/Bradford. | ||||
| Storage & Stability | This product remains stable for 6 months at -80°C or below. Avoid repeated freeze-thaw cycles. |
| Target Background | KIR2DL4 is an unusual killer cell immunoglobulin-like receptor (KIR) family member in terms of its structure, expression, cellular localization, and signaling properties. The most conserved KIR in evolution, it is referred to as a framework KIR gene and is expressed by all natural killer (NK) cells and a subset of T cells. |
| Synonyms | G9P; KIR2DL4; CD158d; KIR-103AS; KIR103AS |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
